Literatur
Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300
Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388
Freedman AN, Yu B, Gail MH et al (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifen or tamoxifen for women age 50 yrs or older. J Clin Oncol (Epub adead of print)
Visvanthan K, Chlebowski RT, Hurley P et al (2009) American Society of Clinical Oncology clinical practice guiedeline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235–3258
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Richter-Ehrenstein, C. Exemestan als Chemoprävention des Mammakarzinoms bei postmenopausalen Frauen. Onkologe 17, 834–836 (2011). https://doi.org/10.1007/s00761-011-2116-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-011-2116-7